HIGHLIGHTS
- who: September and collaborators from the Ain Shams University, Egypt University of Bologna, Italy have published the research: A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma, in the Journal: (JOURNAL)
- what: After combination treatment with TKIs and ICIs failure, single-drug switching significantly prolonged the median SPFS in uHCC patients, and retaining lenvatinib accounted for the survival benefit brought by single-drug switching.
SUMMARY
Combination treatment with TKIs and ICIs has been applied . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.